VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Pseudorabies virus gp50/gp63 mutant vaccine
Vaccine Information
  • Vaccine Name: Pseudorabies virus gp50/gp63 mutant vaccine
  • Target Pathogen: Pseudorabies virus
  • Target Disease: Aujeszky's disease
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Pig
  • gp50 gene engineering:
    • Type: Gene mutation
    • Description: This gp50/gp63 mutant is from Suid herpesvirus 1 (Peeters et al., 1994).
    • Detailed Gene Information: Click Here.
  • gp63 gene engineering:
    • Type: Gene mutation
    • Description: This gp50/gp63 mutant is from Suid herpesvirus 1 (Peeters et al., 1994).
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Pig Response

  • Persistence: A gp50/gp63 mutant is attenuated in pigs (Peeters et al., 1994).
  • Efficacy: A gp50/gp63 mutant vaccine induces protection in pigs from challenge with wild type Pseudorabies virus (Peeters et al., 1994).
References
Peeters et al., 1994: Peeters B, Bouma A, de Bruin T, Moormann R, Gielkens A, Kimman T. Non-transmissible pseudorabies virus gp50 mutants: a new generation of safe live vaccines. Vaccine. 1994; 12(4); 375-380. [PubMed: 8178562].